France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly immunocompromised with frequently associated hypogammaglobulinemia and other chronic conditions. No adverse event was reported.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11328879 | PMC |
| http://dx.doi.org/10.1080/21645515.2024.2387221 | DOI Listing |
Publication Analysis
Top Keywords
patients receive
8
receive sipavibart
8
covid-19 pre-exposure
8
pre-exposure prophylaxis
8
characteristics immunocompromised
4
immunocompromised patients
4
sipavibart early
4
early access
4
access treatment
4
treatment covid-19
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!